statementSaid on 2026-11-11
Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
新華製藥OAB-14乾混懸劑已完成Ⅱ期臨床中國首例患者入組;仍處IPO階段的高光製藥,其腦滲透性TYK2/JAK1抑制劑TLL-041被定位為具有全球首創潛力的神經退行性疾病候選藥物。
Discussion
Related claims
LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.post author · statementSimcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.post author · statementNew Lotus, a supplier of traditional Chinese medicine decoction piece products, listed on its first day.post text · statementThe self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.post author · statementNew Hehua, a supplier of traditional Chinese medicine decoction piece products, opened at HK$51.3 on its first trading day, nearly 28% above its IPO price.香港電台 · statementAfter acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.post author · statement